Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) announced on Thursday a 7% increase in its annualised dividend for 2024, raising it by USD0.20 to USD3.10 per share.
This decision reflects the company's confidence in its performance and cash generation, taking into account other capital allocation priorities as well as acquisitions and business development.
The dividend payment schedule remains unchanged, with announcements made alongside half-year and full-year results and paid in September and March, respectively.
The board also reaffirmed its commitment to AstraZeneca's progressive dividend policy.
Eisai forecasts 73% Leqembi revenue growth in FY 2025, boosting BioArctic royalties
ValiRx subsidiary Inaphaea extends drug repurposing deal with Dominion Biotech
Lilly declares Q2 2025 dividend
Bruker acquires majority stake in RECIPE to expand clinical mass spectrometry diagnostics
Emmaus Life Sciences reports drop in revenues, increased loss in 2024
L'Oréal and WHO Foundation partner to expand global skin health access
Valneva to supply IXCHIQ vaccine for chikungunya outbreak in La Réunion
ANI Pharmaceuticals announces buyout of royalty obligation for ILUVIEN and YUTIQ
Sirum collaborates with Governor Wes Moore to expand medication access across Maryland